Stem Cell Clinic

PRP injections Treatment for Knee – WhaTech Technology and Markets News

By Platelet Rich Plasma Injections

Are you looking for a non-surgical treatment for your knee pain in Philadelphia? Rejuvenate Your Health in Allentown, PA, is here for you.

Rejuvenate Your Health is one of the best Platelet-Rich plasma (PRP) Therapy and Stem Cell therapy specialists in PA. PRP and Stem cell therapy are part of regenerative medicine therapies.

These regenerative medicines are the best non-surgical treatment for joint pain. If you are suffering from joint pain or knee pain, PRP injections can be the best choice for you.

"PRP therapy is like healing your body using itself." By that, they mean using your blood in the process to heal your injury. In PRP therapy, doctors take some of your blood and after processing the blood, they inject it into the place of injury to improve the healing process.

PRP therapy intensifies the body's natural healing process by delivering a higher concentration of platelets to the injured area.

PRP therapy is a simple process and can be performed in the office.

The treatment is performed under the local anesthesia and does not require general anesthesia or hospitalization. Patients can continue their daily work after half-hour from the treatment performed.

Many famous athletes like Philadelphia Phillies Aaron Nola, Tiger Woods and tennis star Rafael Nadal have benefited from PRP therapy.

Dr. Barry Ruht, specializes in body pain management, Stem-cell therapy and PRP injections in Philadelphia. Dr. Ruht and Rejuvenate Your Health, assures that their patients will recover their quickly and painlessly from their injuries.

Dr. Ruht, leads a team full of professionals is dedicated to a patient's recovery and a better life.

If you are unsure or have questions about the treatment and our services, you can contact us anytime. Patient care and satisfaction are considered the highest priority by Dr.

Ruht and his team at Rejuvenate Your Health.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read the rest here:
PRP injections Treatment for Knee - WhaTech Technology and Markets News

A pathway to nowhere? A critique of the National Academy of Sciences report on genome editing – BioNews

By Somatic Stem Cells

12 October 2020

Research Fellow in Biomedical Ethics, University of Melbourne/Murdoch Children's Research Institute

The transformative impact of CRISPR/Cas9 genome editing was recognised last week, with the Nobel Prize being awarded to its founders Jennifer Doudna and Emmanuelle Charpentier.

Since the prize winners first described this new approach to editing DNA, CRISPR has been used for hundreds of applications in biological research, agriculture, conservation biology and somatic medicine. However, its most controversial use has been in human reproduction, a practice called heritable genome editing (HGE). In 2018 Dr He Jiankui, an associate professor at the Southern University of Science and Technology in China announced he had used CRISPR to edit the CCR5 gene in embryos, resulting in twins who had already been born (see BioNews 997). The goal was to make the children resistant to infection from HIV.

Dr He Jiankui's announcement shocked the world and was condemned as a great violation of research ethics. In response, the US National Academy of Medicine, the US National Academy of Sciences, and the UK's Royal Society formed an 'International Commission on the Clinical Use of Human Germline Genome Editing' with the goal of 'defining a responsible pathway for clinical use of human HGE (HHGE), should a decision be made by any nation to permit its use' (see BioNews 1000). The outputs are a list of 11 recommendations that states should follow should they wish to implement HGE.

The strength of the report is the great detail it gives about the technical progress that has been made with genome editing technologies, their current limitations, and the hurdles such technologies should meet before we proceed to clinical applications. The report makes important general points like the need to engage with diverse communities likely to be affected by HGE.

However, in this article, I wish to discuss two reasons to be critical of the report. One concerns its framing and general relevance. The other is the way it categorises different possible future applications of HGE.

Framing and relevance

A convincing need for a clinical pathway for HGE is not provided in the Commission's report. The actions of Dr Jiankui, which were its catalyst, did not challenge our traditional clinical pathways. Dr Jiankui was a rogue actor, who took steps to hide what he was doing from others. His actions were incompatible with basic research ethics principles and existing guidelines for germline genome editing. If the goal is to prevent repeat actors like Dr Jiankui, we need to focus on compliance with existing standards rather than developing new ones.

Furthermore, if a specific clinical pathway for HGE is warranted, it's not clear why you would attempt to define one now. We are still far from having enough evidence to establish the safety of HGE. This will likely remain the case for some time, given restrictions on research in many places. Furthermore, HGE remains illegal in many parts of the world, including the USA, Europe, and the UK. No countries have announced intentions to relax laws and allow HGE, and China has recently passed legislation to restrict it. While the Commission's report is useful for suggesting some safety hurdles that must be cleared (for example recommendations five and six), the fact that we are so far from doing so raises questions about the need for further recommendations. Why not wait until we have safe technologies that some countries are considering implementing before devising detailed clinical pathways? As knowledge of the opportunities and risks posed by HGE increases, a pathway that is currently appropriate for HGE may well be obsolete in the future.

Categorising different applications

To further the above criticism, consider the six categories of HGE applications the Commission's report distinguishes:

A: Cases in which all of the prospective parents' children would inherit the disease-causing genotype for a serious monogenic disease (defined in this report as a monogenic disease that causes severe morbidity or premature death).

B: Cases in which some but not all of the prospective parents' children would inherit the pathogenic genotype for a serious monogenic disease.

C: Cases involving other monogenic conditions with less serious impact.

D: Cases involving polygenic diseases.

E: Cases involving other applications of HGE, including changes that would enhance or introduce new traits or attempt to eliminate certain diseases from the human population.

F: The special circumstance of monogenic conditions that cause infertility.

The Commission considers that only applications in Category A and some in Category B qualify for a clinical pathway. It's no doubt true that the most likely and logical initial application for HGE will be to prevent a serious monogenic disease, in cases where there are no other options. However, it's not clear whether other applications might become more compelling in the future, or indeed if there is a need to draw distinctions like this at all.

Consider how the report deals with applications to prevent infectious disease: a timely application considering we are currently experiencing a pandemic. Applications of HGE which gives individuals resistance to infectious disease are placed in Category E the same category as genes which enhance normal traits like intelligence. We are told a responsible clinical pathway cannot be defined for this application. But consider the following hypothetical case:

A new infectious disease Cebola has become endemic in some parts of the world, and no vaccine is available. Many die of Cebola in childhood. By altering one base-pair, it is possible to make children immune to Cebola. Base editing technologies are developed which can make these changes precisely, with no other changes made in the genome. It is possible to make individuals immune to Cebola by editing embryos used in IVF or editing men's spermatogonial stem cells.

Although such an application of HGE is unlikely, who knows what the world will be like by the time HGE is safe. The fact that this application is classed by the Commission's report in the same category as one which enhances intelligence is problematic, in my view. What is important is whether an application is safe and is expected to do good and prevent harm it doesn't matter ethically whether the harm would have been caused by an inherited disease or an infectious disease. What I think this shows is the need to assess HGE on an application by application basis, and not draw arbitrary distinctions far ahead of time.

Too many reports?

The Commission's report is the latest of dozens into genome editing and will be followed by another by the World Health Organisation soon. What often gets overlooked in these reports is the existing barriers to basic research into genome editing in germ cells, which is illegal or unfeasible in many parts of the world. If our goal is to use HGE to prevent the death and harm caused by genetic disease, we should be focusing on defining pathways that make responsible research easier around the world, rather than prematurely describing clinical pathways.

See the article here:
A pathway to nowhere? A critique of the National Academy of Sciences report on genome editing - BioNews

Should California invest $5.5 billion more into promising stem cell research? – The Mercury News

By Stell Cell Research
  1. Should California invest $5.5 billion more into promising stem cell research?  The Mercury News
  2. Prop. 14 Asks Voters To OK $5.5 Billion In Bonds For Additional Stem Cell Research  KPBS
  3. Editorial: California can't afford unneeded Prop 14 stem cell bond  Desert Sun
  4. What California's 2004 stem cell ballot proposition has meant for University of Southern California  Mirage News
  5. Danette Mitchell: Where I stand on the state propositions  Vacaville Reporter
  6. View Full Coverage on Google News

Original post:
Should California invest $5.5 billion more into promising stem cell research? - The Mercury News

Comprehensive Analysis on Stem Cell Therapy Market based on types and application – AlgosOnline

By Stell Cell Research

The ' Stem Cell Therapy market' study Added by Market Study Report, LLC, provides an in-depth analysis pertaining to potential drivers fueling this industry. The study also encompasses valuable insights about profitability prospects, market size, growth dynamics, and revenue estimation of the business vertical. The study further draws attention to the competitive backdrop of renowned market contenders including their product offerings and business strategies.

The Stem Cell Therapy market research report offers significant information related to the key growth drivers, challenges & limitations, and various opportunities that will define the business scenario in the upcoming years.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=Algosonline.com&utm_medium=AN

According to the research analysis, the Stem Cell Therapy market is estimated to generate commendable returns and showcase a y-o-y growth rate of XX% over the period of 2020-20205.

The advent of COVID-19 pandemic has compelled various businesses to re-establish their respective profit trajectory for the forthcoming years. The study offers a comprehensive assessment of the impact of coronavirus outbreak on the growth of Stem Cell Therapy market.

The document also analyzes the several segmentations and their impact on the growth of this market.

Major highlights from the Stem Cell Therapy market report:

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=Algosonline.com&utm_medium=AN

Stem Cell Therapy Market segments covered in the research report:

Regional segmentation: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Product types: Autologous and Allogeneic

Applications spectrum: Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases and Others

Competitive outlook: Osiris Therapeutics, Molmed, JCR Pharmaceutical, NuVasive, Anterogen, Chiesi Pharmaceuticals, Medi-post, Pharmicell and Takeda (TiGenix

The key questions answered in the report:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Transglutaminase Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-transglutaminase-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Oral Spray Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-oral-spray-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Report : https://www.marketwatch.com/press-release/contactless-payment-market-share-current-and-future-industry-trends-2020-2026-2020-10-12?tesla=y

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

More here:
Comprehensive Analysis on Stem Cell Therapy Market based on types and application - AlgosOnline

How changing the stem cell response to inflammation may reverse periodontal disease – Bite magazine

By Stell Cell Research

Photo: Dmitrii Shironosov 123rf

US scientists have discovered that a specific type of molecule may stimulate stem cells to regenerate, reversing the inflammation caused by periodontal disease.

The current treatment for periodontal disease involves opening the infected gum flaps and adding bone grafts to strengthen the teeth.

But in research published inFrontiers in Immunology, scientists from the Forsyth Institute in Massachusetts have discovered that a specific type of molecule may stimulate stem cells to regenerate, reversing the inflammation caused by periodontal disease.

This finding could lead to the development of new therapeutics to treat a variety of systemic diseases that are characterised by inflammation in the body.

For the study, the team removed stem cells from previously extracted wisdom teeth and placed the stem cells onto petri dishes. They then created a simulated inflammatory periodontal disease environment in the petri dishes. Next, they added two specific types of synthetic molecules called Maresin-1 and Resolvin-E1, both specialised pro-resolving lipid mediators from omega-3 fatty acids.

The scientists found that Mar1 and RvE1 stimulated the stem cells to regenerate even under the inflammatory conditions.

Both Maresin-1 and Resolvin-1 reprogrammed the cellular phenotype of the human stem cells, showing that even in response to inflammation, it is possible to boost capacity of the stem cells so they can become regenerative, Dr Alpdogan Kantarci said.

This finding is important because it allows scientists to identify the specific protein pathways involved in inflammation. Those same protein pathways are consistent across many systemic diseases, including periodontal disease, diabetes, heart disease, dementia, and obesity.

Now that we understand how these molecules stimulate the differentiation of stem cells in different tissues and reverse inflammation at a critical point in time, the mechanism we identified could one day be used for building complex organs, Dr Kantarci said.

There is exciting potential for reprogramming stem cells to focus on building tissues.

Read the original:
How changing the stem cell response to inflammation may reverse periodontal disease - Bite magazine

Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research – Baptist Health South Florida

By Stell Cell Research

October 13th, 2020 Baptist Health South Florida

Boca Raton, FL October 13, 2020 Khalid A. Hanafy, M.D., Ph.D., has joined Marcus Neuroscience Institute at Boca Raton Regional Hospital, part of Baptist Health, as medical director of neurocritical care and director of research. He specializes in the care of subarachnoid hemorrhage patients and the study of neuroinflammation. He also serves as associate professor of neurology at Florida Atlantic University Charles E. Schmidt College of Medicine in Boca Raton. He is board certified in neurology and neurocritical care.

Dr. Hanafy joined Marcus Neuroscience Institute from Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Mass., where he served as the director of the neurological intensive care unit and was an assistant professor of neurology at Harvard Medical School.

We are pleased to welcome Dr. Hanafy to Marcus Neuroscience Institute, said Frank D. Vrionis, M.D., MPH, Ph.D., Institute director and chief of neurosurgery. His clinical skills, research acumen and leadership in the field of neurology will greatly benefit our team and our patients.

As the Institutes director of research, Dr. Hanafy is principal investigator of cutting-edge studies that seek to bring the most advanced, personalized treatments to subarachnoid hemorrhage patients and improve their survival rates and health outcomes. His groundbreaking work in neuroinflammation has been funded by the National Institutes of Health, American Heart Association, American Academy of Neurology, and Massachusetts Institute of Technology. Marcus Neuroscience Institute is at the forefront of stem cell therapeutics, and Dr. Hanafy and Dr. Vrionis have already initiated clinical trials using stem cells in critically ill COVID patients. Together, they will expand research and clinical trials using stem cells for the treatment of other neurological conditions, such as stroke and brain tumors.

Dr. Hanafy has authored more than 40 articles, book chapters and invited editorials in peer-reviewed scientific publications and serves on the editorial boards of scholarly journals in his field. He is a member of several professional societies, including the American Academy of Neurology, Society for Neuroscience Research, Society of Critical Care Medicine, and Neurocritical Care Society.

Dr. Hanafy earned his medical degree and doctorate degree in molecular biology at the University of Texas Medical Scientist Training Program at Houston, a dual degree program of the University of Texas McGovern Medical School and MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. He did his thesis graduate work under Dr. Ferid Murad, the 1998 Nobel laureate. He returned to these Houston facilities to complete a neurology residency following an internal medicine internship at the University of Texas Southwestern at Parkland Memorial Hospital in Dallas. He concluded his medical training with a two-year fellowship in neurological critical care at Columbia University Medical Center in New York City.

About the Marcus Neuroscience Institute The Marcus Neuroscience Institute at Boca Raton Regional Hospital is an innovative nexus for neurologic and neurosurgical care. The 57,000-square-foot facility houses a 20-bed Neuro Intensive Care and Step-Down Unit, four dedicated operating rooms including one equipped with intraoperative MRI and two with intraoperative CT capability and a biplane angiography suite, a crucial component in the diagnosis and care of neurological conditions. The Institute has a staff of five neurosurgeons and nine neurologists who represent some of the most respected clinicians in their fields and is affiliated with Florida Atlantic Universitys Charles E. Schmidt College of Medicine.

About Boca Raton Regional Hospital Boca Raton Regional Hospital is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to our faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the Worlds Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on Facebook, Instagram, Twitter and LinkedIn.

# # #

More here:
Marcus Neuroscience Institute names Khalid A. Hanafy, M.D., Ph.D., Medical Director of Neurocritical Care and Research - Baptist Health South Florida

Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Witness Relatively Significant Growth During Forecast 2020 2027 – re:Jerusalem

By Stell Cell Research

The latestrelease from Database of Data Bridge Market Research has recently published the Global research Report TitledAutologous Stem Cell and Non-Stem Cell Based Therapies Market. The study provides an overview of current statistics and future predictions of the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry-validated market development data.

Europe autologous stem cell and non-stem cell based therapies market is registering a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. The rise in the market can be attributed growing awareness of the therapeutic potential of stem cells in effective disease management and increased public-private investment in the development of stem cell therapies.

Get Free Sample PDF (including COVID19 Impact Analysis) of Autologous Stem Cell and Non-Stem Cell Based Therapies MarketReport@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

(***Our Free Sample Copy of the report gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market and comprising key regions.***)

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Market Attributes

Details

Base Year for Estimation

2019

Historical Data

2016 2019

Forecast Period

2020 2027

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, And Trends

Major Regions as Follows

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

Prominent Key Players Covered in the report:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.Customization Available

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

How Does This Market Insights Help?

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast

Reasons to Purchase this Report

Market Dynamics:The Autologous Stem Cell and Non-Stem Cell Based Therapies report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

COVID-19 Impact Analysis:

The report seeks to track the evolution of the market growth pathways and publish a medical crisis in an exclusive section publishing an analysis of the impact of COVID-19 on the Autologous Stem Cell and Non-Stem Cell Based Therapies market. The new analysis of COVID-19 pandemic provides a clear assessment of the impact on the Autologous Stem Cell and Non-Stem Cell Based Therapies market and the expected volatility of the market during the forecast period. Various factors that can affect the general dynamics of the Autologous Stem Cell and Non-Stem Cell Based Therapies market during the forecast, including current trends, growth opportunities, limiting factors, etc., are discussed in detail in this market research.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Why Is Data TriangulationImportantIn Qualitative Research?

This involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. Triangulation is one method used while reviewing, synthesizing and interpreting field data. Data triangulation has been advocated as a methodological technique not only to enhance the validity of the research findings but also to achieve completeness and confirmation of data using multiple methods

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

See original here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Witness Relatively Significant Growth During Forecast 2020 2027 - re:Jerusalem

The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% -…

By Stell Cell Research

October 08, 2020 05:14 ET | Source: ReportLinker

New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicine Market by Product, Application, Geography - Global Forecast to 2025" - https://www.reportlinker.com/p04700208/?utm_source=GNW However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies.The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019.

The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications.In 2019, the oncology segment accounted for the highest growth rate.

This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World.The North America region is projected to grow at the highest CAGR during the forecast period in 2019.

The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35% By Designation: C-level - 30%, D-level - 20%, and Others - 50% By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World 12%

Lits of companies Profiled in the Report: 3M (US) Allergan plc (Ireland) Amgen, Inc. (US) Aspect Biosystems (Canada) bluebird bio (US) Kite Pharma (US) Integra LifeSciences Holdings Corporation (US) MEDIPOST Co., Ltd. (South Korea) Medtronic plc (Ireland) Anterogen Co., Ltd. (South Korea) MiMedx Group (US) Misonix (US) Novartis AG (Switzerland) Organogenesis Inc. (US) Orthocell Limited (Australia) Corestem, Inc. (South Korea) Spark Therapeutics (US) APAC Biotech (India) Shenzhen Sibiono GeneTech Co., Ltd. (China) Smith & Nephew plc (UK) Stryker Corporation (US) Takeda Pharmaceutical Company Limited (Japan) Tego Science (South Korea) Vericel Corporation (US) Zimmer Biomet (US)

Research Coverage: This report provides a detailed picture of the global regenerative medicine market.It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies.

This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.

Read the full report: https://www.reportlinker.com/p04700208/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

The rest is here:
The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% -...

Was Trump’s Regeneron ‘Cure’ Developed Using Stem Cells and Fetal Tissues? – Snopes.com

By Adult Stem Cells

As governments fight the COVID-19 pandemic, Snopes is fighting an infodemic of rumors and misinformation, and you can help. Read our coronavirus fact checks. Submit any questionable rumors and advice you encounter. Become a Founding Member to help us hire more fact-checkers. And, please, follow the CDC or WHO for guidance on protecting your community from the disease.

As the world raced to find a treatment that would alleviate the global pressure of the coronavirus pandemic, U.S. President Donald Trump contracted the virus in early October 2020 and developed COVID-19, the respiratory disease caused by SARS-CoV-2. In the days following his diagnosis and public release from Walter Reed Hospital, where he received world-class treatment, Trump touted the powers of a miracle drug called Regeneron, which he promised to make available to the American people.

A video shared in tweet by the president on Oct. 7 claimed that Regeneron was a cure.

I spent four days there [at Walter Reed] and I went in, I wasnt feeling so hot. And within a very short period of time, they gave me Regeneron. Its called Regeneron. And other things too but I think this was the key. But they gave me Regeneron, and it was like, unbelievable. I felt good immediately. I felt as good three days ago as I do now.

So, I just want to say, we have Regeneron. We have a very similar drug from Eli Lilly, and theyre coming out and were trying to get them on an emergency basis. Weve authorized it. Ive authorized it. And if youre in the hospital and youre feeling really bad, I think were going to work it so that you get them and youre going to get them free.

Shortly after the president praised what he deemed a cure for his COVID-19 infection, some social media users pushed the claim that the drug Trump was given was developed using fetal tissue a practice in direct conflict with the administrations pro-life platform.

To clarify, Trump was treated with REGN-COV2, a novel anti-viral antibody cocktail created by Regeneron Pharmaceuticals, a New York-based company that has openly stated it uses stem cell and fetal tissues as part of its research and development on new pharmaceutical treatments. This knowledge, and open support from a pro-life president, incited social media pushback from users who argued that the companys use of stem cells and fetal tissues for scientific research goes against pro-life platforms and policies.

REGN-COV2 is a combination of two human-made proteins, or monoclonal antibodies, known as REGN10933 and REGN10987. These two monoclonal antibodies were specifically designed to block the ability of SARs-CoV-2 to infect human cells. The biotechnology company further went on to describe the development of REGN-COV2 as follows:

To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the companys VelocImmune mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the viruss spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population.

While it is true that Regeneron has used stem cells for some of its research, no human stem cells or human embryonic stem cells were used in the development of REGN-COV2, according to Alexandria Bowie, a spokesperson for the company. An April 2020 statement issued by Regeneron confirmed that research using stem cells helps its scientists model complex diseases, test new drug candidates, and lead to scientific insights that may help spur the creation of new medicines but the company contends that embryonic cells were not used in the production of REGN-CO2.

In short: we did not use human stem cells or human embryonic stem cells in the development of REGN-COV2, Bowie told Snopes in an email.

But its not quite that cut and dried.

In the research and development of pharmaceutical therapeutics, many companies turn to what is known as a cell line. These are cultures of human or animal cells that are derived from a living organism and cultured and propagated repeatedly, and, in some cases, used indefinitely. The development of REGN-COV2 utilized HEK293T a cell line that is derived from human fetal embryonic kidney tissues to create a pseudovirus that mimics a spike Protein found in SARS-CoV-2 in order to test the drugs ability to neutralize and ultimately treat the novel coronavirus.

HEK293s are considered immortalized cells (not stem cells) and are a common and widespread tool in research labs. This cell line was originally derived by adenovirus transformation of human embryonic kidney cells in 1977, explained Bowie, adding that HEK293 were further transformed at Stanford in the 1980s with SV40 large T antigen, a solution that is used by researchers to initiate and maintain DNA replication necessary for creating cell lines.

Fetal tissues were not directly used n the development of REGN-COV2, but cell lines from decades-old embryonic kidney tissues were. Fetal tissues are used to develop cell lines. Embryonic stem cells, on the other hand, are different than adult stem cells in that they are undifferentiated and regenerative cells, which means that they have not been assigned a key task in the human body. As such, researchers have uncovered ways to direct their use in creating human tissues that allow for a variety of uses, including testing new pharmaceuticals.

Opposition to the use of fetal tissue and embryonic stem cell research has been at the heart of the pro-life platform due to the way in which these cells are obtained and its association with using living fetuses either inside (in utero) or outside of the uterus (ex utero). Pro-life groups like March for Life have even gone so far as to pressure the Trump administration to halt funding for research that requires aborted fetal organs and tissues. In summer 2019, the president required any federally funded research using fetal tissue to undergo an ethics review, and has since stocked his cabinet with other similarly-minded officials.

REGN-COV2 is currently in late-stage clinical trials for various populations, including non-hospitalized and hospitalized patients as well as for the potential prevention in individuals who may have had close household exposure to COVID-19. According to a news release published on Sept. 29, the company announced that the antibody cocktail was shown to reduce the viral load and alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 also showed positive trends in reducing medical visits. However, it is important to note that the research included a relatively small sample size of just 275 patients.

The greatest treatment benefit was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response. These patients were less likely to clear the virus on their own and were at greater risk for prolonged symptoms, said Regeneron President and Chief Scientific Officer Dr. George D. Yancopoulos in a statement.

As of Oct. 12, Regeneron had submitted an emergency use authorization (EUA) to the U.S. Food and Drug Administration in early October, and noted REGN-COV2s early, promising clinical data paired with the continued, pressing unmet need of COVID-19 meets the FDA standard for emergency use authorization.

Regeneron told Snopes that it cant speculate on potential timing for an EUA. We will update when such is available.

See the rest here:
Was Trump's Regeneron 'Cure' Developed Using Stem Cells and Fetal Tissues? - Snopes.com

The complicated story of Trump’s COVID treatment, stem cells and abortion politics – Baptist News Global

By Adult Stem Cells

The irony cannot be missed: A Rose Garden event to announce the nomination of a Supreme Court justice widely expected to tilt the court toward limiting access to abortion became a super-spreader event for coronavirus, which infected many of the dignitaries gathered there. And the miracle cure touted by the president himself was made possible in some way by the scientific use of aborted fetal tissue.

Since the announcement that President Donald Trump was treated with an experimental cocktail of drugs that he said has made him feel better than he has in 20 years, attention has increasingly focused on how one of those treatments a cocktail of antibodies manufactured by Regeneron was developed and tested. And the same may be true for the other drug used on Trump and other coronavirus patients, Remdesivir.

Two ironic facts have risen to the surface and have been confirmed by multiple sources, however: (1) The new molecular treatment was developed and/or tested in some way involving cells originally derived from an aborted fetus; and (2) the very kind of research that made this therapy possible was shut down by the Trump administration within the past year.

The very kind of research that made this therapy possible was shut down by the Trump administration within the past year.

Critics cite these facts as evidence of hypocrisy by abortion opponents who for years have lambasted stem cell research as barbaric and immoral but now are willing to laud a miracle drug made possible by that very research.

On the other hand, some pro-life advocates dispute the actual use of aborted cells in the research or claim the original cells were obtained so long ago that there is no moral jeopardy in the modern drug.

One Dallas-based medical ethicist noted privately: I understand that many vaccines in the past included a cell line derived from the lung tissue of aborted fetuses, but I have also read that the cell line is either so attenuated or even absent that even the Catholic Church has withdrawn its objections.

And therein lies the nuance of this situation.

Amid these competing claims and an effort by Regeneron to carefully thread the needle of disclosure the MIT Technology Review published an article Oct. 7 by Antonio Regalado that minced no words:

This week, President Donald Trump extolled the cutting-edge coronavirus treatments he received as miracles coming down from God. If thats true, then God employs cell lines derived from human fetal tissue.

The MIT article continues to explain that the antibody treatment Trump received was developed with the use of a cell line originally derived from abortion tissue, according to Regeneron Pharmaceuticals, the company that developed the experimental drug.

And heres where things get quite technical.

According to the MIT journal and other published sources, the molecules in the treatment Trump received are manufactured in cells from a hamsters ovary not in human cells. However, cells originally derived from a fetus were used in another way. According to Regeneron, laboratory tests used to assess the potency of its antibodies employed a standardized supply of cells , whose origin was kidney tissue from an abortion in the Netherlands in the 1970s.

These cells have been immortalized, which means they have been reproduced, divided and shared many times through the years, so that the line of cells used today is, in a way, a descendant of the original cells obtained from the aborted kidney tissue.

Because the cells were acquired so long ago, and have lived so long in the laboratory, they are no longer thought of as involving abortion politics.

Thus the MIT journal concludes: The two antibodies Regeneron eventually put forward as an experimental treatment, which may have saved Trumps life, would have been selected using exactly such tests. Because the cells were acquired so long ago, and have lived so long in the laboratory, they are no longer thought of as involving abortion politics.

In June 2019, the Trump administration blocked federal funding for new scientific research using fetal tissue derived from abortions.

Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trumps administration, the Department of Health and Human Services said in a statement.

And then this important line: Intramural research that requires new acquisition of fetal tissue from elective abortions will not be conducted.

The Trump administration policy hailed widely as a victory for the anti-abortion cause restricted new acquisition of fetal tissue.

The New York Times quoted an administration official who said the presidents acceptance of this coronavirus treatment should not be seen as a contradiction. The administrations policy on fetal tissue research specifically excluded cell lines made before June 2019, said the official, who did not wish to be identified because he was not authorized to speak about the matter. Scientific products made using cell lines that existed before then would not implicate the administrations policy on the use of human fetal tissue from elective abortions, the official said.

The fact that most anti-abortion advocates have remained silent about this apparent contradiction also was addressed by the MIT journal: Most likely, their hypocrisy was unwitting. Many types of medical and vaccine research employ supplies of cells originally acquired from abortion tissue. It would have taken an expert to realize that was the case with Trumps treatment.

In June 2019, the journal Nature reported on the Trump administrations ban on fetal-tissue research that receives federal funding, especially through the National Institutes of Health.

Scientists employ fetal tissue to explore topics as diverse as infectious disease, human development and disorders of the eye.

The administration said it will set up an ethics-review board to evaluate each NIH grant application that would support research with fetal tissue, which is collected from elective abortions. But the government has already decided against renewing its contract with a laboratory at the University of California, San Francisco, that uses fetal tissue to study HIV, Nature reported. The announcement comes after a sustained push by abortion opponents to limit scientific research with fetal tissue despite warnings from researchers that using the tissue is the only way to study some health problems. Scientists employ fetal tissue to explore topics as diverse as infectious disease, human development and disorders of the eye.

The journal quoted UCSF chancellor Sam Hawgood saying this government decision was politically motivated, shortsighted and not based on sound science. Todays action ends a 30-year partnership with the NIH to use specially designed models that could be developed only through the use of fetal tissue to find a cure for HIV.

The New York Times reported that the ethics board set up to review proposed uses of fetal stem cells in research met for the first time in July and in August, the board rejected 13 of the 14 proposals it reviewed; the approved proposal relied on tissue that had already been acquired.

The ethical debate over this kind of research is not going away and, in fact, could escalate as work continues on COVID-19 vaccines.

The New York Times quoted David Prentice, vice president of the Charlotte Lozier Institute, who wrote in September: One concern regarding the ethical assessment of viral vaccine candidates is the potential use of abortion-derived cell lines in the development, production or testing.

Prentices own analysis found 13 vaccine candidates that rely in some way on fetal cell lines.

In response, the Times quoted James Sherley, a research scholar at the Charlotte Lozier Institute and director of the adult stem cell company Asymmetrex, who said this kind of research is not morally responsible. There are alternatives there are lots of ways that dont require the death of anyone.

Additional reporting on this issue has been published in Science magazine and Input magazine.

Related articles:

Is this election all about abortion? It depends on who you ask

See more here:
The complicated story of Trump's COVID treatment, stem cells and abortion politics - Baptist News Global

→←